Related Experiment Video
Updated: Jul 15, 2026
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
Emerging treatments and gene expression profiling in high-risk medulloblastoma
Iacopo Sardi1, Duccio Cavalieri, Maura Massimino
1Department of Pediatrics, Onco-hematology and Neuro-surgery Units, University of Florence Medical School, A. Meyer Children's Hospital, Florence, Italy. i.sardi@meyer.it
Abstract:
The past decades have seen an increase in the survival rates of patients with standard-risk medulloblastoma. Efforts have, therefore, been focused on obtaining better results in the treatment of patients with high-risk tumors. In addition to consolidated therapies, novel approaches such as small molecules, monoclonal antibodies, and antiangiogenic therapies that aim to improve outcomes and quality of life are now available through new breakthroughs in the molecular biology of medulloblastoma. The advent of innovative anticancer drugs tested in brain tumors has important consequences for personalized therapy. Gene expression profiling of medulloblastoma can be used to identify the genes and signaling transduction pathways that are crucial for the tumorigenesis process, thereby revealing both new targets for therapy and sensitive/resistance phenotypes. The interpretation of microarray data for new treatments of patients with high-risk medulloblastoma, as well as other poor prognosis tumors, should be developed through a consensus multidisciplinary approach involving oncologists, neurosurgeons, radiotherapists, biotechnologists, bioinformaticists, and other professionals.
Insights
Advances in medulloblastoma molecular biology offer novel therapies for high-risk tumors. Gene expression profiling aids personalized treatment strategies and identifies new therapeutic targets for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Survival rates for standard-risk medulloblastoma have improved.
- Focus is shifting towards enhancing treatment for high-risk medulloblastoma.
- Molecular biology breakthroughs are driving new therapeutic strategies.
Purpose of the Study:
- To explore novel therapeutic approaches for high-risk medulloblastoma.
- To leverage molecular insights for personalized cancer therapy.
- To identify new drug targets and understand treatment resistance.
Main Methods:
- Utilizing gene expression profiling to analyze medulloblastoma tumors.
- Identifying crucial genes and signaling pathways in tumorigenesis.
- Interpreting microarray data for treatment implications.
Main Results:
- Novel therapeutic strategies including small molecules, monoclonal antibodies, and antiangiogenic therapies are emerging.
- Gene expression profiling reveals critical pathways and potential therapeutic targets.
- Identification of sensitive and resistant phenotypes is possible.
Conclusions:
- Personalized therapy for brain tumors is advancing with innovative anticancer drugs.
- A multidisciplinary approach is essential for interpreting complex data and guiding treatment.
- Targeted therapies based on molecular profiling hold promise for high-risk medulloblastoma.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers